131 related articles for article (PubMed ID: 32902907)
1. Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma.
Cui J; Dean D; Wei R; Hornicek FJ; Ulmert D; Duan Z
J Orthop Res; 2020 Nov; 38(11):2362-2372. PubMed ID: 32902907
[TBL] [Abstract][Full Text] [Related]
2. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.
Slemmons KK; Mukherjee S; Meltzer P; Purcell JW; Helman LJ
Pediatr Blood Cancer; 2021 Feb; 68(2):e28771. PubMed ID: 33063919
[TBL] [Abstract][Full Text] [Related]
3. ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P; Roth ME; Wang Y; Zhang W; Gill JB; Harrison DJ; Teicher B; Erickson S; Gatto G; Smith MA; Kolb EA; Gorlick R
Mol Cancer Ther; 2021 Mar; 20(3):535-540. PubMed ID: 33298592
[TBL] [Abstract][Full Text] [Related]
4. Expression and Clinical Significance of High-Mobility Group AT-hook 2 (HMGA2) in Osteosarcoma.
Cui J; Dean D; Hornicek FJ; Yi G; Duan Z
Orthop Surg; 2022 May; 14(5):955-966. PubMed ID: 35388973
[TBL] [Abstract][Full Text] [Related]
5. Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma.
Ma H; Li X; Wang J; Hornicek FJ; Garbutt CC; Chang X; Duan Z
Oncology; 2018; 95(1):52-60. PubMed ID: 29617702
[TBL] [Abstract][Full Text] [Related]
6. Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.
Wei R; Thanindratarn P; Dean DC; Hornicek FJ; Guo W; Duan Z
J Orthop Res; 2020 Sep; 38(9):1952-1964. PubMed ID: 32162720
[TBL] [Abstract][Full Text] [Related]
7. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW; Tanlimco SG; Hickson J; Fox M; Sho M; Durkin L; Uziel T; Powers R; Foster K; McGonigal T; Kumar S; Samayoa J; Zhang D; Palma JP; Mishra S; Hollenbaugh D; Gish K; Morgan-Lappe SE; Hsi ED; Chao DT
Cancer Res; 2018 Jul; 78(14):4059-4072. PubMed ID: 29764866
[TBL] [Abstract][Full Text] [Related]
8. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Ma H; Dean DC; Wei R; Hornicek FJ; Duan Z
Ther Adv Musculoskelet Dis; 2021; 13():1759720X21995069. PubMed ID: 34104229
[TBL] [Abstract][Full Text] [Related]
10. LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer.
Zhu X; You S; Du X; Song K; Lv T; Zhao H; Yao Q
BMC Med Genomics; 2023 Jan; 16(1):10. PubMed ID: 36653841
[TBL] [Abstract][Full Text] [Related]
11. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
Zhang Y; Cheng H; Li W; Wu H; Yang Y
Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-330-5p promotes the development of osteosarcoma by regulating SPRY2.
Wei Q; Li QQ; Zhai XC; Qin L; Li HB; Meng R; Han XF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8761-8770. PubMed ID: 31696462
[TBL] [Abstract][Full Text] [Related]
13. DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas.
Hu T; He N; Yang Y; Yin C; Sang N; Yang Q
J Exp Clin Cancer Res; 2015 Feb; 34(1):22. PubMed ID: 25884381
[TBL] [Abstract][Full Text] [Related]
14. Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer.
Ray U; Jung DB; Jin L; Xiao Y; Dasari S; Sarkar Bhattacharya S; Thirusangu P; Staub JK; Roy D; Roy B; Weroha SJ; Hou X; Purcell JW; Bakkum-Gamez JN; Kaufmann SH; Kannan N; Mitra AK; Shridhar V
Cancer Res; 2022 Mar; 82(6):1038-1054. PubMed ID: 34654724
[TBL] [Abstract][Full Text] [Related]
15. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
16. Exploiting LRRC15 as a Novel Therapeutic Target in Cancer.
Ray U; Pathoulas CL; Thirusangu P; Purcell JW; Kannan N; Shridhar V
Cancer Res; 2022 May; 82(9):1675-1681. PubMed ID: 35260879
[TBL] [Abstract][Full Text] [Related]
17. LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.
Zheng SN; Ge DW; Tang J; Yang J; Yan JW; Qiu JJ; Yin ZW; Ni Y; Zhao L; Chen X; Yang L
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):96-104. PubMed ID: 30657551
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Ma H; Seebacher NA; Hornicek FJ; Duan Z
EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
[TBL] [Abstract][Full Text] [Related]
20. GDF15 promotes osteosarcoma cell migration and invasion by regulating the TGF‑β signaling pathway.
Chen G; Wang M; Liu X
Mol Med Rep; 2019 Nov; 20(5):4262-4270. PubMed ID: 31545486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
